Perseus Proteomics Valuation
Is 4882 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4882 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 4882's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4882's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4882?
Key metric: As 4882 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 4882's PB Ratio? | |
|---|---|
| PB Ratio | 5.6x |
| Book | JP¥1.91b |
| Market Cap | JP¥10.66b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 89.3x |
| Enterprise Value/EBITDA | -9.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 4882's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.8x | ||
4978 ReproCELL | 1.2x | n/a | JP¥10.7b |
7777 3-D Matrix | 10.4x | n/a | JP¥10.9b |
4597 Solasia Pharma K.K | 4.9x | 71.3% | JP¥10.9b |
177A Kohjin Bio | 2.7x | 25.7% | JP¥9.0b |
4882 Perseus Proteomics | 5.6x | n/a | JP¥10.7b |
Price-To-Book vs Peers: 4882 is expensive based on its Price-To-Book Ratio (5.6x) compared to the peer average (4.8x).
Price to Book Ratio vs Industry
How does 4882's PB Ratio compare vs other companies in the JP Biotechs Industry?
| 1 Company | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
2342 Transgenic Group | 0.6x | n/a | US$21.40m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: 4882 is expensive based on its Price-To-Book Ratio (5.6x) compared to the JP Biotechs industry average (3.6x).
Price to Book Ratio vs Fair Ratio
What is 4882's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 5.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 4882's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Tsumura
JP¥368.9b
Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.
4540
JP¥4,858.00
7D
1.2%
1Y
76.3%
Shionogi
JP¥1.8t
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
4507
JP¥2,094.50
7D
-2.1%
1Y
-10.9%
Daito PharmaceuticalLtd
JP¥32.8b
Manufactures and sells pharmaceutical products worldwide.
4577
JP¥2,147.00
7D
1.8%
1Y
8.8%